ライフサイエンスコーパス: intraaortic

1 required mechanical support devices such as intraaortic balloon counterpulsation (7.7%), left ventri

2 erpulsation (IABP group, 301 patients) or no intraaortic balloon counterpulsation (control group, 299

3 complicating acute myocardial infarction to intraaortic balloon counterpulsation (IABP group, 301 pa

4 e use, complications and outcomes with early intraaortic balloon counterpulsation (IABP) in patients

5 o explore the potential benefit of combining intraaortic balloon counterpulsation (IABP) with thrombo

6 The use of intraaortic balloon counterpulsation did not significant

7 In current international guidelines, intraaortic balloon counterpulsation is considered to be

8 Intraaortic balloon counterpulsation was performed in 86

9 port include mechanical ventilatory support, intraaortic balloon counterpulsation, and hemodialysis o

10 ostoperative morbidity included preoperative intraaortic balloon counterpulsation, preoperative serum

11 cal stabilization including thrombolysis and intraaortic balloon counterpulsation.

12 e (aOR, 2.23 [95% CI, 1.60-3.09]; P < .001), intraaortic balloon pump (aOR, 1.65 [95% CI, 1.11-2.44];

13 formed to determine the role of prophylactic intraaortic balloon pump (IABP) counterpulsation after p

14 long-term availability and clinical usage of intraaortic balloon pump (IABP) counterpulsation, there

15 to 2.3; P = .03), need for an intraoperative intraaortic balloon pump (OR = 3.5; CI, 1.2 to 10.9; P =

16 yocardial infarction (P<0.001), preoperative intraaortic balloon pump (P<0.001), intraoperative/posto

17 pump (P<0.001), intraoperative/postoperative intraaortic balloon pump (P<0.001), number of distal ana

18 rgent priority, preprocedure insertion of an intraaortic balloon pump and PCI of a type C lesion.

19 eneity exists with use of AMCS in HF-CS with intraaortic balloon pump being the most common device us

20 Using IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock II) trial

21 nts with CS, derived from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial.

22 An intraaortic balloon pump in place, cardiogenic shock and

23 diabetic patients as well as those requiring intraaortic balloon pump placement.

24 , myocardial infarction within seven days or intraaortic balloon pump required.

25 heart failure in our ICU (67% of them had an intraaortic balloon pump to unload the left ventricle).

26 (5.3% versus 5.5%), serial cardiac indices, intraaortic balloon pump usage (8.5% versus 7.5%), inotr

27 rporeal membrane oxygenation (11%), although intraaortic balloon pump use also varied between centers

28 Patients managed with intraaortic balloon pump versus other forms of MCS (adva

29 Intraaortic balloon pump was the most commonly used AMCS

30 ansmural myocardial infarction, preoperative intraaortic balloon pump, hemodynamic instability, shock

31 dopamine use, epinephrine use, insertion of intraaortic balloon pump, myocardial infarction, or deat

32 ends of CS, percutaneous mechanical support (intraaortic balloon pump, percutaneous ventricular assis

33 se, diabetes, hypertension, and preoperative intraaortic balloon pump.

34 The most common temporary MCS devices were intraaortic balloon pumps (72%), Impella (17%), and veno

35 k unresponsive to inotropes/vasopressors and intraaortic balloon pumps (IABPs).

36 Patients with preoperative intraaortic balloon pumps were excluded.

37 .3% (return to cardiopulmonary bypass, 2.6%; intraaortic balloon pumps, 1.0%; inotrope usage, 0.8%; c

38 pes at 48 hours, an intra- or post-operative intraaortic balloon pumps, or return to cardiopulmonary

39 e HSCs reside, is predominantly localized to intraaortic clusters.

40 the mouse embryo and for their transition to intraaortic hematopoietic cluster (IAHC) cells.

41 n most vertebrate species, such clusters, or intraaortic hematopoietic clusters (IAHCs), derive from

42 tant embryos contain normal numbers of E10.5 intraaortic hematopoietic clusters that express Runx1 an